Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease

被引：201
|
作者：
Pandey, Arvind K. [1 ]
Singhi, Eric K. [1 ]
Arroyo, Juan Pablo [2 ]
Ikizler, Talat Alp [2 ,3 ]
Gould, Edward R. [2 ]
Brown, Jonathan [1 ]
Beckman, Joshua A. [1 ]
Harrison, David G. [4 ]
Moslehi, Javid [1 ,5 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Div Cardiovasc Med, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Med Ctr, Div Nephrol, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Kidney Dis, Nashville, TN 37232 USA
[4] Vanderbilt Univ, Med Ctr, Div Clin Pharmacol, Nashville, TN 37232 USA
[5] Vanderbilt Univ, Med Ctr, Cardiooncol Program, Dept Med, Nashville, TN 37232 USA
来源：
HYPERTENSION | 2018年 / 71卷 / 02期
关键词：
RENAL-CELL CARCINOMA; OXIDE SYNTHASE EXPRESSION; TARGETED CANCER-THERAPIES; FLUID SHEAR-STRESS; NITRIC-OXIDE; BLOOD-PRESSURE; ANGIOGENESIS INHIBITOR; MECHANOSENSORY COMPLEX; TUMOR ANGIOGENESIS; RANDOMIZED-TRIAL;
D O I：
10.1161/HYPERTENSIONAHA.117.10271
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
[No abstract available]
引用
收藏
页码：E1 / E8
页数：8
相关论文
共 50 条
  • [1] Crescentic glomerulonephritis associated with vascular endothelial growth factor (VEGF) inhibitor and bisphosphonate administration
    Stylianou, Kostas
    Lioudaki, Eirini
    Papadimitraki, Elisavet
    Kokologiannakis, George
    Kroustalakis, Nikos
    Liotsi, Christina
    Giannakakis, Konstantinos
    Georgoulias, Vasilios
    Daphnis, Eugenios
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2011, 26 (05) : 1742 - 1745
  • [2] Axitinib—a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor
    Ronan J. Kelly
    Olivier Rixe
    [J]. Targeted Oncology, 2009, 4 : 297 - 305
  • [3] Induction of vascular endothelial growth factor (VEGF) by hyperthermia and/or an angiogenesis inhibitor
    Kanamori, S
    Nishimura, Y
    Okuno, Y
    Horii, N
    Saga, T
    Hiraoka, M
    [J]. INTERNATIONAL JOURNAL OF HYPERTHERMIA, 1999, 15 (04) : 267 - 278
  • [4] Distribution of vascular endothelial growth factor (VEGF) in prostate disease
    Walsh, K
    Sriprasad, S
    Hopster, D
    Codd, J
    Mulvin, D
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2002, 5 (02) : 119 - 122
  • [5] Distribution of vascular endothelial growth factor (VEGF) in prostate disease
    K Walsh
    S Sriprasad
    D Hopster
    J Codd
    D Mulvin
    [J]. Prostate Cancer and Prostatic Diseases, 2002, 5 : 119 - 122
  • [6] VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease
    Barratt, Shaney L.
    Flower, Victoria A.
    Pauling, John D.
    Millar, Ann B.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (05)
  • [7] Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF)
    Stiver, SI
    Dvorak, HF
    [J]. JOURNAL OF CLINICAL LIGAND ASSAY, 2000, 23 (03): : 193 - 205
  • [8] Mechanisms of Drug Resistance to Vascular Endothelial Growth Factor (VEGF) Inhibitors
    Tavakoli, Jahan
    Aragon-Ching, Jeanny B.
    [J]. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2010, 10 (08) : 593 - 600
  • [9] Vascular endothelial growth factor (VEGF) expression and placental vascular response to VEGF
    Szukiewicz, D
    Szukiewicz, A
    Szewczyk, G
    Maslinski, S
    [J]. 22ND MEETING OF THE EUROPEAN SOCIETY FOR MICROCIRCULATION: MICROCIRCULATION AND VASCULAR BIOLOGY, 2002, : 277 - 280
  • [10] Vascular Endothelial Growth Factor (VEGF) and VEGF Receptor Inhibitors in Health and Disease
    Broussy, Sylvain
    [J]. PHARMACEUTICALS, 2024, 17 (07)
12345